Mometasone Furoate

• Evaluation of Allergen Specific Vaccination of Dog Allergic Patients in Swedish Practice Pending
  2024-517649-15-00 Phase IV 1 country Karolinska Institutet
• A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all… Recruiting
  2025-524580-21-00 Phase II/III 1 country Inmunotek S.L.
• Clobetasol, mometasone and tacrolimus therapy in the treatment of vulval lichen sclerosus in the pediatric population. Recruiting
  2024-514003-33-00 Phase III 1 country Uniwersytet Medyczny W Lublinie
• A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CO… Recruiting
  2023-508760-29-00 Phase III 11 countries Eli Lilly & Co.
• A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis Recruiting
  2023-508817-18-00 Phase III 3 countries Eli Lilly & Co.
• Biologic treatment of rhinosinusitis with nasal polyposis in real-world Danish patients - a direct comparison of dupilumab and mepolizumab Ended
  2022-502250-14-00 Phase IV 1 country Rigshospitalet
• A clinical trial evaluating the efficacy and safety of the drugs - cyclosporine and methotrexate in children and adolescents with moderate t… Ended
  2023-509759-15-00 Phase III 1 country Medical University Of Lodz
• A proof-of-concept study of lunsekimig compared with placebo in adults with chronic rhinosinusitis with nasal polyps Ended
  2024-511261-11-00 Phase II 3 countries Sanofi-Aventis Recherche & Developpement
• A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered sub… Ended
  2024-515717-17-00 Phase III 1 country Inmunotek S.L.
• Evaluation of efficacy and safety of 0.1% mometasone furoate cutaneous emulsion compared to its active ingredient-free base and a comparator… Ended
  2024-511583-82-00 Phase III 1 country GALENpharma GmbH
• Characterisation and intervention study in patients with long-term use of nasal decongestants. Ended
  2024-516312-25-00 Phase IV 1 country Universitair Ziekenhuis Gent
• Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from Olea europaea pollen a… Ended
  2024-511383-88-00 Phase II/III 1 country ROXALL Medizin GmbH
• Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy Ended
  2023-505880-35-00 Phase II/III 1 country ROXALL Medizin GmbH
• Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy Ended
  2023-505567-37-00 Phase II/III 1 country ROXALL Medizin GmbH
• Efficacy, Safety, Tolerability Study of LYR-210 Depot in Chronic Sinusitis Ended
  2023-506268-15-00 Phase III 5 countries Lyra Therapeutics Inc.
• Moisturiser effect on atopic dermatitis relapse prevention in children Ended
  2022-501184-41-00 Phase IV 2 countries Aco Hud Nordic AB
• A study to evaluate the efficacy and safety of repeating dose of benralizumab administered SC versus placebo in patients with Eosinophilic C… Ended
  2023-507987-38-00 Phase III 5 countries AstraZeneca AB

Showing 1–17 of 17 trials